<?xml version="1.0" encoding="iso-8859-1" standalone="no"?>
<!DOCTYPE GmsArticle SYSTEM "http://www.egms.de/dtd/2.0.34/GmsArticle.dtd">
<GmsArticle xmlns:xlink="http://www.w3.org/1999/xlink">
  <MetaData>
    <Identifier>26rg10</Identifier>
    <IdentifierDoi>10.3205/26rg10</IdentifierDoi>
    <IdentifierUrn>urn:nbn:de:0183-26rg106</IdentifierUrn>
    <ArticleType>Meeting Abstract</ArticleType>
    <TitleGroup>
      <Title language="en">Myodesopsia &#8211; a benign symptom or a significant pathology&#63;</Title>
    </TitleGroup>
    <CreatorList>
      <Creator>
        <PersonNames>
          <Lastname>Smet</Lastname>
          <LastnameHeading>Smet</LastnameHeading>
          <Firstname>Marc de</Firstname>
          <Initials>Md</Initials>
        </PersonNames>
        <Address>
          <Affiliation>MIOS SA, Lausanne&#47;CH</Affiliation>
        </Address>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
    </CreatorList>
    <PublisherList>
      <Publisher>
        <Corporation>
          <Corporatename>German Medical Science GMS Publishing House</Corporatename>
        </Corporation>
        <Address>D&#252;sseldorf</Address>
      </Publisher>
    </PublisherList>
    <SubjectGroup>
      <SubjectheadingDDB>610</SubjectheadingDDB>
    </SubjectGroup>
    <DatePublishedList>
      <DatePublished>20260910</DatePublished>
    </DatePublishedList>
    <Language>engl</Language>
    <License license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
      <AltText language="en">This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.</AltText>
      <AltText language="de">Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).</AltText>
    </License>
    <SourceGroup>
      <Meeting>
        <MeetingId>M0658</MeetingId>
        <MeetingSequence>10</MeetingSequence>
        <MeetingCorporation>Retinologische Gesellschaft</MeetingCorporation>
        <MeetingName>38. Jahrestagung der Retinologischen Gesellschaft</MeetingName>
        <MeetingTitle></MeetingTitle>
        <MeetingSession>Glask&#246;rper</MeetingSession>
        <MeetingCity>Badenweiler</MeetingCity>
        <MeetingDate>
          <DateFrom>20260703</DateFrom>
          <DateTo>20260704</DateTo>
        </MeetingDate>
      </Meeting>
    </SourceGroup>
    <ArticleNo>26rg10</ArticleNo>
  </MetaData>
  <OrigData>
    <TextBlock name="Text" linked="yes">
      <MainHeadline>Text</MainHeadline><Pgraph><Mark1>Aim:</Mark1> Vitreous floaters (myodysopsia) are not just a trivial annoyance but for some patients a disease with important visual and psychological impacts.  Patients must be taken seriously while attempts must be made to identify new diagnostic methods enabling objective therapy decisions.</Pgraph><Pgraph><Mark1>Method:</Mark1> International publication trends on floaters were tracked with special focus on epidemiology and quality of life impacts. In clinical practice, various imaging methods including OCT techniques and ultrasound have been used to image vitreous opacities. In addition, the influence of floaters on visual performance has been analysed by using straylight measurements (c-quant) and contrast sensitivity testing.</Pgraph><Pgraph><Mark1>Results:</Mark1> Globally there is increasing recognition of the impact of vitreous particularly after 1999. Myodysopsia affects young and old and can significantly impact patients&#39; quality of life. Depression, anxiety, and limitations in their professional lives can result, up to the point of considering suicide. The level of suffering and visual impairment are comparable to those of age-related macular degeneration (AMD) and glaucoma. According to reports, affected individuals are willing to sacrifice one year for every ten years of remaining life expectancy to alleviate their symptoms. Hence, interest in non-invasive treatments is growing.Objectively documenting floaters remains a challenge. New OCT techniques allow for a very detailed view of floaters up to 12 mm from the retina, providing an unparalleled analysis of floater dynamics and positioning inside the vitreous cavity over time. Increased straylight values correlate with visual impairment by floaters, as does a decrease in contrast sensitivity. </Pgraph><Pgraph><Mark1>Conclusion:</Mark1> Myodysopsia represents a true pathology, potentially causing a severe visual handicap. While each patient responds differently to their presence, complaints are real and demand an appropriate tailored response on our part. Modern methods for objective assessment are being developed which individually or in a multimodal approach provide guidance for targeted therapies including non-invasive options next to YAG laser and vitrectomy.</Pgraph></TextBlock>
    <Media>
      <Tables>
        <NoOfTables>0</NoOfTables>
      </Tables>
      <Figures>
        <NoOfPictures>0</NoOfPictures>
      </Figures>
      <InlineFigures>
        <NoOfPictures>0</NoOfPictures>
      </InlineFigures>
      <Attachments>
        <NoOfAttachments>0</NoOfAttachments>
      </Attachments>
    </Media>
  </OrigData>
</GmsArticle>